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Background Clinical benefits of secondary prophylaxis (SP) 
in young-adult severe haemophiliacs are largely debated, as 
only retrospective data are available, often obtained from 
small case-series. In chronic diseases like haemophilia, the 
improvement of quality of life is a primary objective of health-
care interventions, but pharmacoeconomic implications may 
influence therapeutical choices.  
Methods Treatment regimens of severe haemophilic patients 
aged >18 yrs attending our Haemophilia Centre over the last 7 
years were reviewed. Clinical data from 25 patients (median 
age 31 yrs, range 22-53) switched to long-term SP were 
compared to those from 19 age-matched patients who received 
on-demand treatment. Data on quality of life were obtained by 
scores of visual analogue self-rating scales (VAS), on which 
patients reported their perceived treatment satisfaction, 
haemophilia-related physical restrictions, psychological 
impact and social functioning (100 highest, 0 lowest), 
registered every 12-18 months. 
Results Between 2001 and 2007, the rate of patients aged >18 
yrs on SP at our Centre has more than doubled (from 17% to 
39%; from 29% to 57% among patients aged 18-30 yrs).  
Patients started long-term SP (median dose 27 IU/Kg thrice 
weekly) at a median age of 24 yrs (range 18-49). Median 
follow-up was 5.3 yrs (2.4-6.8). Eleven patients used 
recombinant and 14 plasma-derived concentrates; six patients 
switched to recombinant products over the study period. 
Thirteen patients (52%) had a history of target joint(s), but the 
most frequent reasons for starting prophylaxis were the 
increase of bleeding frequency and limitations in physical 
activity. Patients on SP showed a significant lower frequency 
of bleeding episodes (median 6, 0-18 vs. 19, 8-51 per patient-
yr, p<0.01), with a 57% increase of FVIII consumption 
(median 4486 vs. 2556 IU/Kg/yr). Thus, prophylaxis resulted 
in increase of costs of 94,570€ per patient-yr. A good long-
term compliance to SP was registered, only 3 patients (12%) 
reporting withdrawal >3 mo.  
Prophylaxis regimens were tailored according to patient need 
and clinical outcomes in six cases (infusions twice weekly in 
2, each other day in 3 and 5 days per week in one). An 
improved quality of life was documented in patients on 
prophylaxis, among whom 22 (88%) regularly attended 
school/work and 13 (52%) practiced physical activity/sports. 
Significantly lower scores of physical (p<0.001) and 
psychological (p<0.05) restrictions, together to higher 
satisfaction to treatment (p<0.001) and social functioning 
(p<0.01) were reported in patients on SP than in those on-
demand.  
These results were confirmed at repeated assessment over the 
study period. Indirect measures of better quality of life were 
lower numbers of work-school days lost and of visits and 
other health-care interventions in patients on prophylaxis. 
Conclusions Secondary prophylaxis is increasingly prescribed 
among young-adult severe haemophiliacs as a “quality of life-
oriented” and tailored choice of treatment. The undoubted 
increase of costs is associated to significant reduction of 
bleeds and, in parallel, of patients’ physical and psycho-social 
restrictions, improving their participation to active life. The 
increase of direct costs for concentrates should be balanced by 
the reduction of other social and health-related costs. These 
benefits are likely to be also higher at longer follow-up 
evaluations.  
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Background Menorrhagia is the most common cause of iron 
deficiency anaemia in women in fertile age. In most cases 
gynaecological and endocrinological conditions may explain 
the abnormal menstrual loss, however more recently the 
possible contribution of undiagnosed disorders of haemostasis 
has been recognized.  
Methods We investigated the presence of abnormalities of 
primary haemostasis in 38 consecutive young women (15-35 
yrs) referred to our Centre with a history of menorrhagia 
and/or iron deficiency anaemia. Dysfunctional or organic 
gynaecologic abnormalities (pelvic ultrasonography and 
hormonal evaluation) or other clinically detectable causes of 
iron deficiency (including coeliac disease by testing anti-
transglutaminase antibodies and other clear-cut 
gastrointestinal diseases) were excluded.  
The questionnaire for the collection of bleeding history and 
the computation of bleeding score, recently standardized in 
type 1 von Willebrand Disease (VWD), was used at patient 
enrolment. Coagulation assessment, carried out in the first 
week of the menstrual cycle and in the absence of any 
hormonal treatment or signs of inflammatory states, included 
bleeding time (Ivy), PT, aPTT, FVIII:C, VWF:Ag and 
VWF:RCo and in vitro platelet aggregation (Born). Abnormal 
data were confirmed by repeated assessments.  
Results Two patients (5.2%) showed VWF abnormalities 
consistent with type 1 VWD (VWF:RCo<30%, RCo/Ag >0.7). 
In four patients (10.5%) abnormalities of in vitro platelet 
aggregation were detected and further studies led to diagnose 
storage pool disease in two cases and agonist-receptor 
abnormalities in the other two patients. Both VWD patients 
and 2 out 4 patients with platelet defect showed 
responsiveness to desmopressin (normalization of bleeding 
time).  
On the whole, newly diagnosed VWD and abnormalities of 
primary haemostasis were found in 6/38 patients (16%) with 
idiopathic menorrhagia and/or iron deficiency anaemia, all 
with bleeding score >=5. However, as expected, the specificity 
of such finding was 67% in this population.  
Conclusions Despite the limited sample size and the lack of 
objective assessment of menorrhagia, our data support the role 
of underlying disorders of haemostasis as aetiologic/ 
contributory factors in this setting. The standardized 
questionnaires and bleeding scores may be helpful to identify 
